Brady Todd C 4
4 · Aldeyra Therapeutics, Inc. · Filed Mar 31, 2026
Research Summary
AI-generated summary of this filing
Aldeyra (ALDX) CEO Todd C. Brady Receives Equity Awards
What Happened
Todd C. Brady, President, CEO and a director of Aldeyra Therapeutics (ALDX), was granted two equity awards on March 27, 2026: 1,880,510 derivative shares (option) and 632,318 bonus units, both recorded at $0.00 per share (total listed consideration $0). These are awards/derivative grants (transaction code A), not open-market purchases or sales.
Key Details
- Transaction date: 2026-03-27; Form 4 filed 2026-03-31 (filed late relative to the 2-business-day Form 4 requirement).
- Awards: 1,880,510 option-type shares (vesting) and 632,318 bonus units; combined total = 2,512,828 derivative shares. Price reported: $0.00 (grant).
- Shares owned after transaction: Not specified in this Form 4.
- Footnote F1: The option shares vest in equal monthly installments over 48 months of continuous service starting January 1, 2026.
- Footnote F2: The bonus units vest ratably in equal annual installments over four years beginning March 27, 2026; vested bonus units are payable in cash (on the earlier of four years from grant or a Change of Control) equal to the closing market price on the payment date.
- Transaction type: Awards/derivatives (code A); not an immediate purchase or sale.
Context
These are time‑based awards that vest over multiple years and therefore do not represent immediate acquisition of freely tradeable shares. The bonus units are payable in cash upon vesting (or earlier in a change of control), so they are economically different from standard stock grants. Because the Form 4 was filed after the typical 2-business-day deadline, it is noted as late filing in the record.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-03-27+1,880,510→ 1,880,510 totalExercise: $1.77Exp: 2036-03-26→ Common Stock (1,880,510 underlying) - Award
Bonus Units
[F2]2026-03-27+632,318→ 632,318 total→ Common Stock (632,318 underlying)
Footnotes (2)
- [F1]The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2026.
- [F2]The bonus units vest ratably in equal annual installments over a four-year period beginning on March 27, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date.